Sesen Bio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 1800, Cambridge, Massachu...Phone Number
(617) 444-8550Website
www.sesenbio.comRevenue
$40 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Sesen Bio
Sesen Bio is a clinical-stage biotechnology company focused on developing targeted fusion protein therapeutics for cancer treatment. Founded in 2008, the company specializes in research and development of innovative biological treatments for bladder cancer. Their lead product candidate, Vicineum, is designed to treat non-muscle invasive bladder cancer that has not responded to conventional therapies. Sesen Bio has established strategic partnerships with pharmaceutical companies in various global regions to support commercialization efforts. The company maintains worldwide rights to its technology with specific regional exceptions where it has formed commercial partnerships. Sesen Bio is publicly traded and continues to advance its pipeline of targeted cancer therapeutics through clinical trials and regulatory processes.Explore more
Sesen Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sesen Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Sesen Bio is spiking on competitors!
Earning: See what the market has to say on Sesen Bio recently announced quarterly report
Funding: Get notified immidiatlly once Sesen Bio has new funding data
Sesen Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Sesen Bio had a recent Job posting/layoffs
Product Launch: Get notified when Sesen Bio launches new products
Check if Sesen Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Sesen Bio
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Sesen Bio
Find more new buyers
Compare Similar Companies to Sesen Bio
Compare insights from companies similar to Sesen Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sesen Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Sesen Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Sesen Bio.
Sesen Bio financials insights
Gather financial insights about Sesen Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$50M
Sesen Bio Tech Stack
A closer look at the technologies used by Sesen Bio
See more technologies
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
New Hire
Executive Move
As previously announced, Minori Rosales has joined the organization as Chief Development Officer. Previously, Rosales served as Vice President, Clinical Research for MacroGenics.
New Hire
Executive Move
As previously announced, Stephanie Vigue has joined the organization as Director, Finance. Previously, Vigue served as Interim Controller & Corporate Accounting Manager for The FI Company.
New Hire
Executive Move
Sesen Bio News & Media
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update. Business Update On February 13, 2023, following extensive engagement with Sesen Bio stockholders, Sesen Bio and Carisma Therapeutics, Inc. (“Carisma”) further amended the previously amended merger agreement announced on December 29, 2022. The terms of the amended merger agreement include: An increase of the oneSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations
NEW YORK, Feb. 22, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New...Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), in advance of the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023. In reaching its conclusion that stockholders shouldLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023. ISS is widely recognized as a leading independent proxy advisory firm, providing impartial analyse
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Sesen Bio
Sign Up For FreeTo access detailed company insights
Sesen Bio is a clinical-stage biotechnology company focused on developing targeted fusion protein therapeutics for cancer treatment. Founded in 2008, the company specializes in research and development of innovative biological treatments for bladder cancer. Their lead product candidate, Vicineum, is designed to treat non-muscle invasive bladder can... Read More
